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Role of combination therapy in
treating raised LDL cholesterol in
high-risk patients
Cholesterol carried in low-density lipoprotein cholesterol (LDL-C)
and other apolipoprotein B-containing lipoproteins plays a causal role
in atherogenesis,1–3 and, accordingly, is a key target in the prevention
of atherosclerotic cardiovascular disease (ASCVD).2,3 Clinical trial evi-
dence indicates that the magnitude of the benefit from LDL-C lower-
ing is independent of the means by which it is achieved and is
proportionate to the absolute decrease in lipoprotein level.1–4
Further, the relative risk reduction (RRR) appears the same, regardless
of patient demographics and background medical history.1–4 Most
guidelines (e.g. Piepoli et al 2016)2 recommend goals for LDL-C low-
ering that, while somewhat artificial and idealized constructs because
the association between LDL-C and risk is continuous,1 have been
useful clinically as a metric of therapeutic success. In clinical practice,
however, not all patients achieve their LDL-C goal with statins alone,
and increasing recognition of this treatment gap has led to the need to
consider the routine use of combination lipid-lowering therapies.
The cholesterol absorption inhibitor ezetimibe added to statin
achieves an incremental reduction in LDL-C of typically 20–25% and
has been shown to provide a further decrease in ASCVD risk.5 Hence,
this agent is now recommended for patients not achieving their lipid
goal on maximum tolerated statin dose.2,3 Recently, the introduction
of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors has
made possible more profound LDL-C lowering of the order of
50–60%,6,7 and both currently marketed agents—evolocumab and
alirocumab—have been approved for use in selected patient groups
[those with severe ASCVD and those with primary hypercholestero-
laemia, especially familial hypercholesterolaemia (FH)] with an inad-
equate response to maximally tolerated statin therapy or statin
intolerance. With the publication of the FOURIER trial, we have evi-
dence that the addition of PCSK9 inhibitors to statin delivers significant
reduction in the risk of cardiovascular events, in line with the predicted
benefit from meta-regression analysis.8
Cost-effectiveness analyses of
PCSK9 inhibitor therapy
Although current European and US guidelines indicate that the use of
PCSK9 inhibitors is appropriate in specific patients,9,10 uptake has been
low, in most part due to their perceived expense.11 Cost-effectiveness
analyses are essential in determining whether, how, and when PCSK9
inhibitor treatment meets accepted metrics of value for money.
However, the different models published to date have produced widely
varying and potentially confusing results. Eight reports on the health
economics of PCSK9 inhibitor use have appeared: four academic-
led12–15 and four supported by industry.16–19 Of these, three analyses
were based on the FOURIER data.14,15,19 In addition, health technology
appraisals were undertaken by the UK National Institute for Health
and Care Excellence (NICE) for alirocumab and evolocumab.20
According to the US Institute for Clinical and Economic Review
(ICER) analysis, the use of PCSK9 inhibitors did not meet a threshold
of cost-effectiveness, defined in the study as $100 000 per quality-
adjusted life year (QALY) gained, in patients with heterozygous FH
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(primary prevention) or ASCVD.12 The analysis was based on the
Cardiovascular Disease Policy Model that adopted a US health sys-
tem perspective and a price for PCSK9 inhibitors of $14 350 per
annum. Estimates of LDL-C reduction were based on the published
literature, and statins, ezetimibe, and PCSK9 inhibitors were all
assumed to achieve similar reductions in the risk of cardiovascular
events per mg/dL decrease in LDL-C. Addition of a PCSK9 inhibitor
to statin in ASCVD patients was estimated to save 4.3 million major
cardiovascular events with an increment of 7.9 million QALYs at a
cost of $414 000 per QALY gained. This analysis was updated
recently using the findings of the FOURIER trial.14 Cost-effectiveness
was recalculated at $450 000 per QALY in ASCVD patients, com-
pared with eztimibe, a less optimistic value than the initial estimate;
the authors stated that price reductions of the order of >71% would
be required to meet the $100 000 per QALY threshold.
In a further US-based analysis, Arrieta et al.13 assumed annual costs
of $14 000–$15 000, and a hypothetical patient population based on
those enrolled in the OSLER-1 and -2 extension studies,6 with starting
LDL-C levels of 120 mg/dL. Again, the authors concluded that PCSK9
inhibitors are not cost-effective, with an estimated incremental cost of
approximately $350 000 per QALY compared with background ther-
apy. In contrast, the US-based model developed by Gandra et al.16
estimated an incremental cost-effectiveness ratio of only $75 800 per
QALY for the lifetime use of evolocumab (based on an annual price of
$14 139) in patients with heterozygous FH. Corresponding estimates
for patients with ASCVD and statin-intolerant ASCVD were
$141 700 and $100 300 per QALY. In this model comparing evolocu-
mab with background therapy, baseline LDL-C levels were high at
156.5 mg/dL in heterozygous FH, 141.3 mg/dL in ASCVD, and
189.4 mg/dL in statin-intolerant ASCVD. The magnitude of LDL-C
lowering was based on data from Phase 3 studies and estimated effects
on cardiovascular event rates on the meta-analysis of statin trials (22%
reduction in events per 1.0 mmol/L reduction in LDL-C).4
The model by Toth et al.17 also reported cost-effectiveness of evo-
locumab, based on ‘real-world’ cardiovascular disease (CVD) burden
data (which in general reveal patients to be at higher risk than is seen
in clinical trial cohorts) from the UK Clinical Practice Research
Datalink, and assuming a payer discount of >20% for the price of evo-
locumab (list price $14 100). The target patient population was
derived from eligibility criteria in the FOURIER study8 and predicted
reductions in cardiovascular event rates were based on meta-regres-
sion.4 For patients with ASCVD and baseline LDL-C levels >_70 mg/
dL and >_100 mg/dL, the justifiable value-based price range under a
willingness-to-pay threshold of $150 000 per QALY gained for evolo-
cumab was $11 990–$16 856.
In a study from the Spanish National Health System perspective,
Villa et al.18 concluded that evolocumab may be cost-effective, assum-
ing a target population with FH or prior cardiovascular event history,
LDL-C >100 mg/dL, LDL-C lowering as in Phase 3 trials, cardiovascu-
lar event reduction again based on meta-regression,4 and lifetime
treatment at a cost of e4969 per annum. Incremental cost-
effectiveness ratios were found to be e30 893 for FH and e45 340
for the secondary prevention population.
Finally, based on the FOURIER data applied to a real-life US popula-
tion and assuming a 29% price discount, Fonarow et al.19 found an
incremental cost-effectiveness ratio of $166 000 per QALY. These
authors did not compare with ezetimibe but with standard background
therapy. The baseline risk level corresponded to a total (initial plus
recurrent) cardiovascular event rate of 6.4 per 100 patient-years.
Hernandez did not perform a cost-effectiveness analysis but calcu-
lated the societal impact of a health outcomes-based agreement
whereby industry would not charge for PCSK9 inhibitors for those
patients with events despite treatment.15 The author concluded that
such a scheme would not lead to sufficiently low prices.
Assessments of alirocumab and evolocumab conducted by NICE
indicated that these drugs could be cost-effective in the UK National
Health Service setting.20 The approach assumed annual alirocumab
costs of £4383 and starting LDL-C levels of 3.5 mmol/L for hetero-
zygous FH patients with CVD and non-FH patients at very high risk,
4.0 mmol/L for non-heterozygous FH patients at high risk for CVD,
and 5.0 mmol/L for heterozygous FH patients without CVD. LDL-C
lowering was informed by the ODYSSEY trials,7 and the hazard ratio
per 1.0 mmol/L reduction in LDL-C was estimated at 0.79.4 Example
incremental costs per QALY gained for alirocumab were estimated
as £37 000 (LDL-C >_4 mmol/L) for heterozygous FH primary pre-
vention, £24 000 (LDL-C >_2.5 mmol/L) for heterozygous FH secon-
dary prevention, £44 300 (LDL-C >_2.5 mmol/L) for patients with
‘high-risk’ CVD, and £34 000 (LDL-C >_2.5 mmol/L) for patients at
‘very high risk’.
There are noteworthy issues in the models described above. For
example, Villa et al.18 assumed that the risk reduction of heart failure
was the same as that of myocardial infarction. If that assumption is
not made, the cost-effectiveness ratio increases to e62 000 per
QALY. A further consideration is the treatment of stroke. In the
report by Kazi et al.,12 the disutility applied to this outcome was sur-
prisingly low, and because FOURIER found a significant stroke benefit
from only 2 years of treatment,8 this would lead to an underestimate
of cost-effectiveness.
However, as indicated by Toth et al.,17 the variation in outcome
from these cost-effectiveness studies is driven (next to the assumed
acquisition cost of the medicines) primarily by the estimation of abso-
lute risk (of both first and recurrent events) rather than fundamental
differences in modelling approach. Ongoing risk of future cardiovascu-
lar events is hard to define precisely for the populations of interest,
given the dearth of long-term follow-up data in FH and the wide range
of risk in subjects with established ASCVD.2,3,21 With the above eco-
nomic results in mind, it seems more appropriate at the moment to
base the use of these agents on a stratification of risk and benefit than
to promulgate general deployment in secondary prevention.
‘Highest risk–highest benefit’
approach to PCSK9 inhibitor use
The first element of a potentially useful ‘stratified-medicine’ strategy
is to define ‘highest risk’, i.e. those with the highest baseline event
rate. The level of risk required to justify the use of PCSK9 inhibitors
will preclude their use in asymptomatic individuals without prevalent
vascular disease (primary prevention), with the exception of FH with
high LDL-C despite statin therapy, and so secondary prevention is
the main focus. ‘Highest risk’ categories are polyvascular disease,
ASCVD with co-morbidities such as chronic kidney disease or diabe-
tes with end-organ damage or FH patients with a CVD event
(Table 1).20–22 In this context, it would be worthwhile applying the
‘Highest risk–highest benefit’ strategy for PCSK9 inhibitor use 2547
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.. risk stratification tools as has been done for acute coronary syn-
drome patients with ezetimibe/statin combination therapy.21 The
second element is to identify patients receiving the ‘highest benefit’.
Because the RRR is proportionate to the absolute decrease in LDL-C
level in mmol/L,1–4 and the magnitude of percent LDL-C reduction
with PCSK9 inhibitor therapy appears similar across baseline LDL-C
subgroups,6,7 then patients with the highest starting LDL-C will
achieve the greatest absolute reduction in LDL-C and hence the
greatest RRR on the drugs.
Given the above, it is possible to construct a relatively simple matrix
that provides a framework for optimizing the use of these agents.
Figure 1 depicts the gradient of ‘number needed to treat’ (NNT, over
5 years) based on the estimated risk of a future ASCVD event, the
starting LDL-C, and the average RRR associated with a drug-induced
LDL-C drop of 60%.6–8 Estimated NNT is lower (incremental cost-
effectiveness ratio lower) in individuals with the greatest CVD risk and
largest absolute LDL-C reduction. This is a conceptual expansion of
the tables generated by NICE (in TA393 and TA394)20 and the
approach advocated by Robinson et al.22
Depending on the prevailing price of PCSK9 inhibitors, bands of
NNT that are payer-acceptable could be defined as an aid to pre-
scribers—this is shown in the shaded green regions in Figure 1. For
example, in the NICE alirocumab appraisal, it was calculated that, to
.................................................................................................
Table 1 Categories of ‘highest risk’ for ASCVD
(around or above a benchmark of 30% 10-year risk) on
statin therapy, based on published trial data
Category Projected 10-year
risk on moderate-
or high-intensity
statin therapy (%)
Clinical ASCVD þ diabetes 28–38
No CKD 26–29
With CKD 28–43
Clinical ASCVD þ CKD 34–35
Recent acute coronary syndrome (<3 months) 32
CHD and poorly controlled risk factors 28–41
CHD and peripheral vascular disease 43–55
CHD and age >_65 years 21–54
Stroke/transient ischaemic attack and male 31
CHD and familial hypercholesterolaemia
(baseline LDL-C >_190 mg/dL)
41
ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease;
CKD, chronic kidney disease.
Adapted from Robinson et al.22
Figure 1 ‘Highest risk–highest benefit’ strategy for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor use. The schematic shows LDL-C
on optimum statin/ezetimibe therapy on the vertical axis and risk of a cardiovascular disease event on the horizontal axis. Predicted relative risk
reduction (RRR) associated with a PCSK9 inhibitor-induced 60% decrease in LDL-C is in the first column. This is based on a 22% risk reduction per
1.0 mmol/L drop in LDL-C as derived by meta-regression4 and confirmed by the FOURIER investigators.8 Number-needed-to-treat (NNT) (recipro-
cal of the absolute risk reduction) is provided per 5% increment in risk and 1.0 mmol/L increment in LDL-C in the other columns. These are given
for a 5-year timescale. Varying cost profiles are represented by the shades of green. A low-cost jurisdiction may permit NNT <30 as an acceptable
threshold; medium-cost NNT <20; and high-cost NNT <15.22 For illustration purposes, markers are provided for the approximate NNT for the
average FOURIER subject (FA; LDL-C 92 mg/dL, estimated annual risk 3.3%), a FOURIER subject in the top LDL-C quartile (F4; LDL-C 126 mg/dL;
annual risk 3.8%),8 and the National Institute for Health and Care Excellence (NICE)-approved categories (NVH—very high-risk, i.e. polyvascular dis-
ease or multiple events, LDL-C >3.5 mmol/L; NFH—FH no event with LDL-C >5.0 mmol/L). Rx, prescription.
2548 L. Annemans et al.
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achieve the cost-effectiveness threshold of £30 000 per QALY
gained, the baseline LDL-C level would need to be 5.0 mmol/L for
primary prevention in FH and3.5 mmol/L in very high-risk patients.
Similarly, Robinson et al.22 showed that addition of a PCSK9 inhibitor
provides a 5-year NNT <_50 to prevent one cardiovascular event in
very high-risk and high-risk patients with LDL-C >_70 mg/dL and a 5-
year NNT <_30 for very high-risk and high-risk patients with LDL-C
>_130 mg/dL. It should be noted that in most health care systems, it is
likely that the ‘prevailing price’ will need to be substantially below the
list price for these drugs to be cost-effective in a broad range of target
patient types (and greater transparency on drug discounts would aid
decision-making). The strategy depicted in Figure 1 captures not only
the potential clinical benefit for patient types at a given LDL-C level
but also could be used to formulate the cost-effectiveness to society
based on the range of NNT considered appropriate to an overall
budget for these agents.
Conclusion
A simple strategy is needed to help physicians in the selection of
patients suitable for PCSK9 inhibitor therapy, and we commend the
‘highest risk–highest benefit’ concept and advocate the development
of simple aids (such as Figure 1) for clinicians to implement this frame-
work. The aids should be adapted to the prevalent cost of these
drugs in various pricing jurisdictions.
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